Product image of Inlyta (Axitinib) supplied by GNH India

Inlyta

Active Ingredient:
Axitinib
Origin:
EU

Inlyta (Axitinib)

Axitinib, the active ingredient in Inlyta, is a selective tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of metastatic renal cell carcinoma in adult patients, where it helps to inhibit tumor‑driven blood vessel formation by targeting vascular endothelial growth factor receptors, reducing angiogenesis and tumor progression.

GNH India supplies Inlyta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, providing reliable access to this oncology medication.

Manufacturer / TM Owner

Pfizer Europe Ma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Inlyta (axitinib) is used in the management of cancers that rely on VEGF‑driven angiogenesis.
  • Metastatic renal cell carcinoma: improves progression‑free survival in adults with advanced disease.
  • Advanced renal cell carcinoma after prior therapy: offers an additional treatment option when first‑line agents have failed.
  • Renal cell carcinoma with VEGF pathway activation: targets angiogenesis to slow tumor growth.

How It Works

  • Axitinib selectively inhibits the intracellular tyrosine kinase activity of vascular endothelial growth factor receptors VEGFR‑1, VEGFR‑2 and VEGFR‑3. By blocking these receptors, the drug interferes with downstream signaling pathways that promote endothelial cell proliferation, migration and new blood‑vessel formation, thereby reducing tumor angiogenesis and limiting cancer growth.

Side Effects

Common Side Effects

  • Hypertension: elevated blood pressure requiring monitoring and management.
  • Diarrhea: may be mild to moderate and manageable with supportive care.
  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: occasional upset stomach or vomiting.

Serious or Rare Side Effects

  • Arterial thromboembolism: risk of blood clots in arteries.
  • Gastrointestinal perforation: rare but severe gut wall injury.
  • Severe hemorrhage: potentially life‑threatening bleeding events.

Precautions & Warnings

Patients receiving Inlyta should be monitored for several safety considerations.

  • Monitor blood pressure: check regularly and treat hypertension promptly.
  • Assess liver function: evaluate hepatic enzymes before and during therapy.
  • Evaluate wound healing: postpone elective surgery while on treatment.
  • Review cardiovascular risk: use caution in patients with prior thromboembolic events.
  • Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Avoid Interactions

Axitinib may interact with other medicines that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): increase axitinib exposure.
  • Strong CYP3A4 inducers (e.g., rifampin): decrease axitinib exposure.
  • Potent CYP3A4 substrates with narrow therapeutic index: risk of altered levels.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: additive blood‑pressure lowering effect.
  • Anticoagulants (e.g., warfarin): may increase bleeding tendency.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): elevate risk of gastrointestinal bleeding.
  • Other VEGF pathway inhibitors: potential for overlapping toxicities.

Frequently Asked Questions

Inlyta contains the active ingredient axitinib and is used to treat metastatic renal cell carcinoma in adult patients. It works by inhibiting blood‑vessel formation that supplies the tumor, helping to slow disease progression.

Axitinib selectively blocks the tyrosine kinase activity of VEGFR‑1, VEGFR‑2 and VEGFR‑3. This inhibition prevents the signaling cascade that drives angiogenesis, thereby reducing the growth of new blood vessels that tumors need to expand.

The prescribed dose of Inlyta is determined by the treating physician based on the patient’s clinical condition, prior therapies and tolerance. Dosage adjustments may be made according to response and any observed side effects.

Safety of axitinib in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and to discontinue breastfeeding while on treatment, unless the benefits outweigh potential risks as assessed by a healthcare professional.

To request Inlyta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inlyta (axitinib) is a highly selective VEGFR inhibitor with a relatively short half‑life, allowing flexible dose adjustments. Compared with broader‑spectrum agents, axitinib may offer a distinct safety profile, but efficacy and tolerability should be evaluated individually by the prescribing oncologist.

Inlyta tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Keep the medication away from moisture and direct sunlight to maintain stability.

Inlyta is taken orally as a tablet, usually with or without food, as directed by the prescribing physician. Patients should follow the exact schedule and instructions provided on the prescription label.

Serious risks include arterial thromboembolism, gastrointestinal perforation, and severe hemorrhage. Patients should be monitored closely for signs of blood clots, abdominal pain, or unusual bleeding, and report any such symptoms immediately to their healthcare provider.

Inlyta is contraindicated in patients with known hypersensitivity to axitinib or any tablet excipients. Caution is advised for individuals with uncontrolled hypertension, recent major surgery, or a history of severe cardiovascular events, and the drug should be avoided in these cases unless a specialist determines it is appropriate.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Axitinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT